[Antibodies to cardiolipin and tumor-associated antigens CA-125 and CA-19-9 in patients with ovarian tumors]

Klinicheskaia meditsina · 1996 · vol. 74(4) , pp. 42–5 · PMID:8999153 · W118012633
Other OA: closed CC0
View on OpenAlex View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-08-26 ⓘ

This study found that antibodies to cardiolipin and tumor markers CA-125 and CA-19-9 are frequently elevated in ovarian tumors, particularly endometriosis, with parallel changes suggesting an autoimmune origin for ovarian endometriosis.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Antibodies to cardiolipin (ACL) were detected in 12 (35%) of 34 patients with tumors of the ovaries. 8 of 12 patients exhibited clinical signs of antiphospholipid syndrome, 9 (75%), 2 and 1 patients demonstrated isolated hyperproduction of IgG ACL, combined rise of IgG ACL and IgM ACL, IgM ACL, respectively. Most frequently ACL occurred in endometriosis of the ovaries and serous cystadenomas (50 and 60%, respectively). In 5 (42%) of 12 patients CA-125 antigen concentration was above the upper norm (35 U/ml), in 3 (25%) cases the level of CA 19-9 antigen was elevated. There were parallel changes of ACL concentration and tumor marker CA-125 before and after operation. Autoimmune origin of ovarian endometriosis is suggested.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Antibodies, Anticardiolipin Antibodies, Neoplasm CA-125 Antigen CA-19-9 Antigen Ovarian Neoplasms Adult Adult Aged Aged Antibodies, Anticardiolipin Antibodies, Anticardiolipin Antibodies, Neoplasm Antibodies, Neoplasm CA-125 Antigen CA-125 Antigen CA-19-9 Antigen CA-19-9 Antigen Female Female Humans

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-08T06:18:23.926119+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-10-08T22:00:02.201502+00:00
License: CC0 · commercial use OK